Related Experiment Video
Updated: Feb 28, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
Published on: June 9, 2021
Characterization of cardiac disease-associated mutations in RyR2 Ca2+- and caffeine-binding sites
Venkat R Chirasani1,2, Akanksha Patwardhan3,4, Naohiro Yamaguchi3
1Department Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Abstract:
Cardiac Ca2+ release channels, type-2 ryanodine receptors (RyR2s), play a pivotal role in cardiac muscle contraction by releasing Ca2+ from the sarcoplasmic reticulum. Over 200 missense mutations in humans have been reported to be associated with cardiac diseases. Here, we characterize three RyR2 variants, Q3925E, W4646R, and Q4937K. Q3925E and W4646R mutations are in the Ca2+- and caffeine-binding sites, respectively. Our molecular dynamics simulations predicted that the Q4937 residue in the carboxyl terminal domain forms a hydrogen bond with the central domain where the Ca2+-binding site is located. Three mutant RyR2s were expressed in heterologous cells, and activities of the recombinant mutant RyR2 channels were determined by [3H]ryanodine binding methods. As expected, Q3925E greatly reduced Ca2+-dependent activation and W4646R abolished caffeine activation. Our novel finding is that Q3925E increased inhibitory effects by divalent cations, Ca2+ and Mg2+, resulting in a strong loss-of-function phenotype. Both W4646R and Q4937K increased affinities for Ca2+ activation, and reduced or unchanged Ca2+ inhibitions, exhibiting typical gain-of-function phenotypes. Caffeine failed to activate the Q3925E mutant at resting Ca2+ but restored its activation at ∼20 µM Ca2+, where the Q3925E mutant is in the subactivated state. Computational analysis of the mutated structures suggested that the Q3925E mutation does not reduce Ca2+ binding to its site but rearranges domain interface between the central domain involving Ca2+-binding site and carboxyl terminal domain, which directly interacts with the channel pore. Thus, it is possible that the Q3925E-RyR2 mutation alters signal transmission between activating Ca2+ binding and pore opening.NEW & NOTEWORTHY Q3925E in RyR2 is a part of Ca2+-binding site and is known to associate with cardiac sudden death. Our functional and structural modeling data suggested that the Q3925E mutation does not reduce Ca2+ binding but alter a domain interaction, causing an impaired Ca2+ activation of RyR2. We also found that the Q3925E mutation increases channel inhibition by Mg2+ and Ca2+, resulting in a strong loss-of-function phenotype.
More Related Videos
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...